Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radioiodinated anti-carcinoembryonic antigen M5A
- Development stage
- Unknown
- Lead developer
- City of Hope National Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Radioiodinated anti-carcinoembryonic antigen M5A is a radiopharmaceutical comprising the humanized monoclonal antibody M5A labeled with a radioisotope of iodine, such as Iodine-131 (131I) or Iodine-124 (124I). M5A is an intact IgG1 antibody engineered from the murine T84.66 antibody to target carcinoembryonic antigen (CEA; CEACAM5), a glycoprotein frequently overexpressed in solid tumors, particularly colorectal and pancreatic carcinomas. The radioiodinated conjugate is designed for targeted imaging (immuno-PET) or radioimmunotherapy, leveraging the high specificity of the M5A antibody for CEA-expressing cells to deliver localized radiation. Preclinical studies have demonstrated that M5A exhibits superior tumor retention and a longer serum half-life compared to smaller antibody fragments like diabodies or minibodies, although it is subject to in vivo dehalogenation (loss of the iodine label).
- Other names
- 131I-M5A124I-M5A125I-M5Aradioiodinated hM5Aradioiodinated humanized anti-CEA M5A
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on radioiodinated anti-carcinoembryonic antigen M5A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radioiodinated anti-carcinoembryonic antigen M5A.